Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01083849 · OUTCOME

Time to Achieve Target Range of Intact Parathyroid Hormone (iPTH) Levels Within the Target Range After 12 Months

Long-Term Therapy Outcomes When Treating Chronic Kidney Disease (CKD) Patients With Paricalcitol in German and Austrian Clinical Practice · Source last updated 2014-12-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
days
Interval / dispersion
Standard Deviation
Time frame
Up to 12 months

What was measured

Participants achieved Intact Parathyroid Hormone (iPTH) levels within the target range of Kidney Disease Quality Outcome Initiative (K/DOQI) treatment guidelines (Chronic Kidney Disease (CKD), stage 3: 35 to 70 pg/mL; CKD stage 4: 70 to 110 pg/mL; CKD stage 5: 150 to 300 pg/mL).

Analysis population: Participants with a determined chronic kidney disease (CKD) stage

Groups in this outcome

Paricalcitol

Participants with chronic kidney disease and a diagnosis of secondary hyperparathyroidism, not treated with paricalcitol for at least 6 months prior inclusion in this study, received paricalcitol injection or capsules, on an on-label basis in an everyday setting. Participants were observed for 12 months.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Paricalcitol718

Reported measurements

Stage 3 [N=17]
Values in days · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Paricalcitol212.4203.93Not reportedNot reportedNot reported
Stage 4 [N=25]
Values in days · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Paricalcitol195.5118.3Not reportedNot reportedNot reported
Stage 5 [N=407]
Values in days · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Paricalcitol145.7107.1Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        203.93
        value
        212.4
    title
    Stage 3 [N=17]
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        118.3
        value
        195.5
    title
    Stage 4 [N=25]
  3. categories
    1. measurements
      1. group Id
        OG000
        spread
        107.1
        value
        145.7
    title
    Stage 5 [N=407]
denoms
  1. counts
    1. group Id
      OG000
      value
      718
    units
    Participants
description
Participants achieved Intact Parathyroid Hormone (iPTH) levels within the target range of Kidney Disease Quality Outcome Initiative (K/DOQI) treatment guidelines (Chronic Kidney Disease (CKD), stage 3: 35 to 70 pg/mL; CKD stage 4: 70 to 110 pg/mL; CKD stage 5: 150 to 300 pg/mL).
dispersion Type
Standard Deviation
groups
  1. description
    Participants with chronic kidney disease and a diagnosis of secondary hyperparathyroidism, not treated with paricalcitol for at least 6 months prior inclusion in this study, received paricalcitol injection or capsules, on an on-label basis in an everyday setting. Participants were observed for 12 months.
    id
    OG000
    title
    Paricalcitol
param Type
MEAN
population Description
Participants with a determined chronic kidney disease (CKD) stage
reporting Status
POSTED
time Frame
Up to 12 months
title
Time to Achieve Target Range of Intact Parathyroid Hormone (iPTH) Levels Within the Target Range After 12 Months
type
PRIMARY
unit Of Measure
days

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice